To understand the relationship between circRNF220 and miR-30a targets in AML samples, we determined the relative abundances of those genes with respect to GAPDH in our panel of samples from 22 primary AML patients, 8 AML patients with complete remission, 3 relapse patient and 3 healthy controls. This evidence concerns the gene GAPDH and acute myeloid leukemia.